Successful infection by mucosal pathogens requires overcoming the mucus barrier. To better understand this key step, we performed a survey of the interactions between human respiratory mucus and the human pathogen S. pneumoniae. Pneumococcal adherence to adult human nasal fluid was seen only by isolates expressing pilus-1. Robust binding was independent of pilus-1 adhesive properties but required Fab-dependent recognition of RrgB, the pilus shaft protein, by naturally-acquired secretory immunoglobulin A (sIgA). Pilus-1 binding by specific sIgA led to bacterial agglutination, but adherence required interaction of agglutinated pneumococci and entrapment in mucus particles. To test the effect of these interactions in vivo, pneumococci were preincubated with human sIgA prior to intranasal challenge in a mouse model of colonization. sIgA-treatment resulted in rapid immune exclusion of pilus-expressing pneumococci. Our findings predict that immune exclusion would select for non-piliated isolates in individuals who acquired RrgB-specific sIgA from prior episodes of colonization with piliated strains. Accordingly, genomic data comparing isolates carried by mothers and their children showed that mothers are less likely to be colonized with pilus-expressing strains. Our study provides a specific example of immune exclusion involving naturally-acquired antibody in the human host, a major factor driving pneumococcal adaptation.
Introduction

Results
Pneumococci interact with human nasal mucus via mucosal proteins 105
Colonizing Spn are found predominantly within the glycocalyx, the mucus layer 106 overlaying the epithelial surface (12) . We established an in vitro assay to study Spn interactions 107 with human mucus, considering both attachment and detachment. The association of 108 encapsulated Spn (isolate TIGR4) with immobilized pooled human nasal fluid (hNF) collected 109 from healthy adults was quantified by using a solid-phase assay with BSA as blocking reagent. 110
Spn adhered to hNF more readily compared to bovine submaxillary mucus, which has been 111 recently used in a similar approach (13) (Fig. 1A ). Adherence to either source of mucus was 112 higher than controls with BSA alone. As a control for the functionality of the assay, we 113 demonstrate that adherence of an isogenic capsule-deficient mutant to hNF was significantly 114 increased as previously described for bovine submaxillary mucus ( Fig. 1B) (13) . 115
Next, we considered whether Spn interactions with hNF involved binding to host 116 carbohydrate moieties and/or protein(s). hNF was pretreated with either sodium periodate 117 (NaIO 4 ) to oxidize oligosaccharides or trypsin to degrade protein. Even high concentrations of 118 sodium periodate did not affect the binding of Spn to hNF (Fig. 1C) . In contrast, incubation of 119 hNF with increasing concentrations of trypsin reduced the adherence of Spn in a concentration-120 dependent manner (Fig. 1D ). Inhibition of trypsin activity restored adherence levels equivalent to 121 those without added protease. 122
Three of the most abundant proteins in hNF include lactoferrin, sIgA, and lysozyme ( Fig.  123 2A, B, C) (24). The pneumococcal surface protein A (PspA) and the pilus-1 have been shown to 124 bind to purified human lactoferrin (25, 26) . In addition, pneumococcal surface protein C 125 (PspC/CbpA) interacts specifically with secretory component of human sIgA (27, 28) . 126
Furthermore, a recent study suggests the interaction of the pilus-1 with the extracellular domain 127 of polymeric immunoglobulin receptor (pIgR) that is identical to secretory component (29) . To 128 assess the relevance of these interactions in human nasal secretions, we incubated whole 129 TIGR4 or defined mutants lacking these surface proteins with soluble hNF and detected bound 130 lactoferrin or sIgA by flow cytometry. Our data confirmed that PspA is the major protein 131 responsible for lactoferrin recruitment to the Spn surface ( Fig. 2D , dot plots in Fig. S1 ). The 132 mutant lacking the entire pathogenicity islet expressing pilus-1 did not display impaired binding 133 of mucosal lactoferrin. However, lack of pilus-1 resulted in a 72% reduction in binding of sIgA 134 when compared to the isogenic parental strain. The pspC-deletion mutant also showed a 135 significant impaired binding of mucosal sIgA, however, to a lesser extent than the pilus-deficient 136 mutant. Loss of PspA did not alter the acquisition of sIgA to the bacterial surface. PspA, PspC 137 and the pilus-1 are immunogenic in humans and antibodies to these surface factors, which likely 138 result from prior exposure during colonization episodes, are common (30) (31) (32) (33) (34) . Therefore, we 139 also analyzed the binding of IgG in hNF to Spn and found no significant difference between wild 140 type Spn and the protein-deficient mutants. Overall, the results demonstrate a role for 141 interactions between bacterial factors and host mucosal proteins: PspAlactoferrin and pilus-1 142 / PspC -sIgA. 143 144 Pilus-1 is the major factor interacting with human mucus 145
The minority of clinical S. pneumoniae isolates expresses the pilus-1 (35-37). We 146 screened clinical isolates for pilus expression by immunoblotting and confirmed the presence or 147 absence of the pilus-1 pathogenicity islet by PCR using primers within rrgB (Fig. S2) . To 148 examine a contribution of the pilus-1 in Spn adherence to hNF, we used, in addition to the 149 TIGR4 strain, two piliated (types 9V and 19F) and two non-piliated (types 6A and 23F) clinical 150 isolates. Over a time period of 5h, adherence levels of the pilus-expressing strains were similar 151 to the TIGR4 reference strain, while adherence of the non-piliated strains was significantly lower 152 compared to TIGR4 (Fig. 3A) . Detachment was quantified as a further measure of the strength 153 of interaction between Spn and hNF. In comparison to piliated strains, the non-piliated strains 154 detach significantly more readily from the nasal mucus ( Fig. 3B ). To further confirm the role of 155 pilus-1 in Spn binding to immobilized hNF, we used pilus-1-deficient constructs of the TIGR4, 156 9V, and 19F strains and a pilus-1-islet knock-in mutant of the 23F strain. Again, adherence to 157 hNF correlated with pilus expression over genetic background (Fig. 3C, D, E, F) . In addition, 158 the rrgA and rrgB genes of the 9V and 19F strain were sequenced and both belong to the 159 common clades which include TIGR4 ( Fig. S3/4 ). Overall, adherence to hNF of the mutants 160 without the pilus-1 islet was reduced 4 to14-fold. Furthermore, adherence of the piliated strain 161 was reduced to the levels of the non-piliated mutant by pretreatment of hNF with trypsin ( Fig  162   S5 ). In contrast to pilus-1, we were unable to detect a role for PspA or PspC in adherence to 163 immobilized hNF ( Fig. 3C , F) despite the role of these Spn proteins in binding factors in human 164 nasal secretions ( Fig. 2D , dot plots in Fig. S1 ). Our findings show that the pilus-1 is the major 165
Spn surface structure mediating binding of S. pneumoniae to normal human nasal mucus from 166
adults. 167
Next, we determined which specific component of the pilus is involved in binding to 168 human mucus. The pilus-1 is composed of three subunits: the tip RrgA, which is also described 169 as adhesin, the shaft RrgB, and the ancillary protein RrgC (26, (37) (38) (39) (40) . We performed solid-170 phase assays and flow cytometry using pneumococcal mutants, which lacked one or two pilus-1 171 components. Adherence of the rrgA-deficient strain was slightly but significantly reduced in 172 comparison to WT (Fig. 4A ). The rrgB-deletion mutant was most impaired in adherence to hNF. 173
The absence of the pilus-1 subunit RrgC did not impact Spn adherence and loss of both RrgB 174 and RrgC resulted in levels comparable to the single rrgB-deletion mutant (Fig. 4A) . 175
Additionally, recruitment of sIgA from soluble hNF by each of the mutants directly correlated 176 with their capability to adhere to immobilized mucus ( Fig. 4B , dot plots in Fig. S6 ). To further 177 verify a contribution of RrgA and RrgB in binding to hNF, we performed an inhibition assay using 178 specific antibodies against these pilus-1 components. WT Spn pre-treated with either anti-RrgA 179 or anti-RrgB antisera adhered significantly less to hNF compared to controls (Fig. 4C ). Blocking 180 of RrgB resulted in a greater inhibitory effect and consequently lower levels of Spn adherence 181 compared to the blocking of RrgA. As expected, the pre-treatment of the pilus-1 deficient mutant 182 with the RrgA-and RrgB-specific antibodies had no effect on the adherence to human nasal 183 fluid ( Fig. 4C ). Together, these findings suggest that the pilus-1 shaft-forming subunit RrgB is 184 the main Spn factor bound by human mucus, with a small contribution from the tip component 185
RrgA. 186 187
Pneumococcal pilus-1 is a major determinant responsible for human sIgA recruitment 188
Based on the impaired sIgA-binding of the pilus-1-deficient mutant when incubated with 189 hNF, we analyzed the acquisition of human sIgA (purified from pooled colostrum) to the Spn 190 surface using flow cytometry. Because of the binding of PspC to the human secretory 191 component of sIgA, a pspC-deficient mutant was used as control. sIgA bound in a 192 concentration-dependent fashion to the surface of the TIGR4 as well as to the isogenic pilus-1-193 and pspC-deficient mutants (Fig. 5A ). Deletion of the pilus-1-islet decreased sIgA-acquisition by 194 up to 78%, whereas the lack of PspC reduced binding of sIgA only up to 38%. To decipher 195 whether binding of this immunoglobulin isotype is exclusive for sIgA, we also analyzed binding 196 of pooled human serum IgA. Based on the dimeric structure of sIgA and the resulting tetrameric 197 valency of the molecule, monomeric divalent serum IgA was used in a 2-fold molar ratio. 198
Interestingly, recruitment of serum IgA by the non-piliated mutant was lower in comparison to 199 the binding of sIgA. However, when the pilus-1 is expressed, the binding of serum IgA to the 200 bacterial cell surface is similar to that of sIgA. This observation was confirmed using the non-201 piliated 23F parental strain and its isogenic pilus-1-knock in mutant. When pilus-1 is expressed, 202
Spn bound higher amounts of human sIgA (Fig. 5B) . Surprisingly, the pilus-1 seems to be the 203 main pneumococcal determinant capable of binding large amounts of human sIgA. Furthermore, 204
due to the recruitment of serum IgA, binding is not specific to secretory component, suggesting 205 that binding is mediated by the Fab-portion and is independent of the secretory component or 206 the J-chain only present in sIgA. We confirmed this interpretation by performing binding studies 207 with cleaved sIgA using WT Spn and the pspC-deficient mutant as control. Binding of the sIgA 208 Fab α -portion to Spn was maintained after cleavage with recombinant IgA1-protease ( Fig. 5C,D) . 209
In contrast, acquisition of the heavy chain comprising the Fc-portion, the secretory component, 210 and the J-chain, was significantly reduced after protease treatment ( Fig. 5C, E) . The residual 211 binding of the heavy chain was mediated entirely by PspC. These findings reveal an 212 immunodominant antigen-antibody interaction between pneumococcal pilus-1 and naturally-213 acquired human sIgA. 214
In addition, we analyzed the contribution of pilus-1 in Spn binding of purified human 215 lactoferrin and pooled serum IgG, two other components of nasal secretions. As shown in 216 Figure 2D , pilus-1 is not involved in recruitment of lactoferrin or IgG to the Spn surface ( Fig.  217 5F,G). Our findings confirm PspA as the main surface protein responsible for binding of 218 lactoferrin. 219 220 sIgA is not the only factor required for pneumococcal adherence to human nasal fluid. 221
As well as assessing the binding of Spn to pooled hNF, we tested pilus-1-mediated Spn 222 adherence to hNF from six individual healthy adult donors. Spn adhered to all tested hNF 223 samples in a pilus-1-dependent manner ( Fig. 6A ). We analyzed further whether all hNF samples 224 contain anti-pilus sIgA and verified the presence of anti-RrgB sIgA within the hNF from 225 individual adults ( Fig. 6B ). Using purified sIgA as competitor for Spn binding to hNF showed that 226 adherence of WT Spn, but not the pilus-1-deficient mutant was inhibited ( Fig. 6C ). This effect 227 was greater for sIgA than an equivalent titer of serum IgA. Due to the inhibitory effect of sIgA, 228 these findings suggest that the sIgA-pilus-1 interaction plays the main role in Spn binding to 229 hNF. Furthermore, we immobilized purified sIgA and BSA (same protein concentration as hNF) 230
and performed the solid-phase assay. WT Spn did not adhere to pilus-1-specific sIgA, 231
suggesting that sIgA alone is not sufficient to mediate adherence ( Fig. 6D) . 232
Human nasal fluid agglutinates pilus-expressing S. pneumoniae 234
Next, we examined whether hNF is able to agglutinate pilus-expressing bacteria. Indeed, 235
we could visualize the formation of immune complexes of piliated Spn but not the pilus-deficient 236 mutant (Fig. 7A ). The pilus-deficient strain appeared mostly as diplococci and were distributed 237 uniformly in the hNF. In contrast, the pilus-expressing bacteria were more often found 238 associated with mucus particles in which they form longer chains (threading, an early stage of 239 agglutination) and aggregates (41). Likewise, purified human sIgA (same anti-RrgB titer as hNF) 240 agglutinated Spn in a pilus-dependent manner ( Fig. 7B ). 241
Nasal mucus forms a highly heterogeneous network in which the mucins form 242 heterotypic complexes with other mucosal proteins such as sIgA (42). We therefore wanted to 243 check whether the composition and integrity of mucus are necessary for Spn binding, or if 244 human sIgA alone mediates Spn binding. We centrifuged hNF to sediment large mucus 245 particles and performed the solid-phase assay with the resulting supernatant. We observed that 246 WT Spn adherence is reduced to a level comparable to that of the pilus-1-deficient mutant. (Fig  247   7C ). The supernatant of centrifuged hNF still contains sIgA able to agglutinate piliated Spn. 248
However, as shown in Fig. 6D , sIgA alone does not mediate Spn adherence. Our results 249 suggest that the interaction between mucus particles and Spn, which has been agglutinated by 250 sIgA, is necessary for Spn binding to hNF. 251 252
Secretory IgA inhibits acquisition of colonization by pilus-expressing pneumococci 253
A variety of functions of mucosal sIgA have been proposed, including neutralizing 254 released bacterial factors, agglutination of bacteria, and inhibiting bacterial attachment to the 255 epithelium (22, 23, (43) (44) (45) (46) (47) . Given the importance of sIgA in protection of the respiratory 256 epithelium, we tested whether human sIgA targeting the type 1 pilus could prevent the 257 establishment of Spn colonization in vivo. Using a mouse model of competitive infection, adult 258 mice were intranasally (i.n.) challenged with equal numbers of the piliated TIGR4 and its 259 isogenic non-piliated mutant. Before administration, bacteria were pre-incubated with either a 260 physiologically relevant concentration of human sIgA or PBS as control. Because of the 261 potential of sIgA to disrupt early events in colonization, we determined the competitive index 262 (CI) as early as 4 h and 22 h post-infection. In the absence of human sIgA, WT and the non-263 piliated mutant established equal levels of colonization (CI approximately equal to 1) ( Fig. 8A  264 and C). This indicated a minimal effect of pilus in early colonization in the murine model. When 265 pre-incubated with human sIgA, which contains naturally-acquired antibody to pilus-1, pilus-266 expressing Spn were impaired in establishing colonization relative to the non-piliated mutant at 267 4 and 22 h post-challenge. The experiment was then repeated using human serum IgA (at a 268 titer to pilus-1 equivalent to sIgA). Serum IgA did not select against the piliated strain indicating 269 that structural differences in the characteristics of secretory immunoglobulin are needed for this 270 effect ( Fig. 8A ). Additionally, sIgA was pre-treated with recombinant IgA1-protease to eliminate 271 its multivalent binding. Protease cleavage, which was confirmed by Western analysis (Fig. 8B) , 272 was sufficient to eliminate selection against the piliated strain. Since the protease is specific for 273 sIgA1, this result also suggested that any contribution of sIgA2 is secondary. Overall, these 274 findings suggest that naturally-acquired sIgA specific to the pneumococcal pilus-1 is able to 275 inhibit colonization acquisition. 276
Spn expresses a cell-surface-anchored protease (Iga, ZmpA) with specificity for human 277 IgA1, the predominant immunoglobulin in nasal secretions (48, 49) . Cleavage of human IgA1 in 278 the hinge region generates monovalent Fab α -fragments, eliminating its capacity to agglutinate 279 its target (50, 51) . This would predict that the IgA1 protease would limit agglutination-dependent 280 adherence. When tested in the solid phase assay with hNF, however, the protease-deficient 281 mutant showed slightly decreased rather than increased adherence ( Fig 8D) . This observation 282 correlates with a previous report showing that IgA1-mediated adherence of Spn to epithelial 283 cells is enhanced by the enzyme (52). In addition, absence of the IgA1-protease had no effect 284 on immune exclusion by human sIgA in the competition assay in vivo, (Fig. 8E) . 285 286
Pilus-expressing pneumococci preferentially colonize children 287
Given our results in vitro and in mice, we hypothesized that human adults, who have had 288 more cumulative exposure to S. pneumoniae, will have higher levels of mucosal anti-pilus sIgA. 289
As a result, piliated strains may be preferentially excluded during the establishment of adult 290 carriage, and thereby be less commonly found when compared to carriage in children from the 291 same population. 292
To test this hypothesis, we analyzed genomic data produced from S. pneumoniae 293 isolates taken from asymptomatic carriage episodes in unvaccinated mothers and their children 294
(53). We tested for an association between the presence of pilus in the colonizing strain and 295 whether the host was an infant or adult. We excluded infants under six months of age because 296 of maternal antibody. In a naive association, we find adults are less likely to be colonized by 297 pilus-expressing strains, which is significant at the genome-wide level (Table 1 -OR = 2.23; p = 298 2.0x10 -13 ). When controlling for the genotypic background of the colonizing strain, as in a 299 genome-wide association study, we found no significant association (p = 0.50). Given the strong 300 association between pilus presence and specific strains, this latter result is unsurprising (54). We examined the interactions of a mucosal pathogen with mucus-containing human 312 secretions. Our results first confirmed the binding of Spn surface proteins PspA and PspC to the 313 mucus components lactoferrin and secretory component, respectively (25, 27) . The dominant 314 interaction of Spn with hNF from adults, however, involved the binding of naturally-acquired 315 specific sIgA to a single antigen, the main pilus-1 subunit, RrgB. Binding of sIgA to Spn 316 expressing pilus-1 promoted agglutination and the association of bacterial aggregates (immune 317 complexes) with mucus particles. In a mouse model of upper respiratory tract colonization, 318 pretreatment with human sIgA enhanced rapid pilus-1-dependent Spn clearance. Thus, our 319 findings provide an antigen-specific demonstration of mucosal defense with natural antibody via 320 immune exclusion; the consecutive events of agglutination, mucus entrapment and removal of 321 pathogens by mucociliary activities (22). 322
It was unexpected that a single antigen could account for the majority of Spn adherence 323 to mucus-containing secretions. Pilus-1 is one of many immunogenic surface components but is 324 expressed by only a minority of Spn isolates (less than 20% in adults from the population we 325 analyzed) (31, 33, 35) . This suggests that the pilus locus is subject to negative frequency-326 dependent selection, where the population-wide fitness advantage is higher the rarer the locus. 327
It has been shown that negative frequency-dependent selection on genes present in only a 328 minority of the population are a major driving force of pneumococcal population dynamics (55). 329
Our work gives an example of mechanism for this important form of selection, whereby immune 330 exclusion of piliated strains mediated by sIgA would increase as population prevalence of pilus-331 1 increases. 332
Naturally-acquired immunoglobulin to other surface structures, including the main 333 surface antigen capsular polysaccharide, is common in adults (30, 34, 54) , but based on our 334 findings apparently does not contribute in a significant manner to the association of Spn with 335 human nasal mucus. More than 70% of sIgA binding to Spn was attributable to pilus-1 (Figs. 2A, 336 5A) . In contrast to other Spn surface components, the pilus-1 protrudes up to 1 µm from the cell 337 surface where it is no longer shielded by the thick layer of capsular polysaccharide (26). Thus, 338 the physical properties of pilus-1 may allow for binding of sIgA against RrgB>>RrgA that had 339 been generated through exposure during prior carriage events. (22). In our mouse model, however, there was no apparent contribution of 353 pilus-1 to adherence since early colonization of pilus-expressing and non-expressing strains 354
were equivalent, suggesting a human-specific benefit. Therefore, anti-pilus-1 sIgA does not act 355 by impeding an adhesive function but rather through its agglutinating activity. Secretory IgA, 356 which is polymeric (quadrivalent), is more effective at agglutinating piliated Spn compared to 357 serum IgA, which is primarily monomeric (divalent). Several reports document the protective 358 role of secretory polymeric immunoglobulin against mucosal pathogens (58-60). The importance 359 of the agglutination function of anti-capsular human immunoglobulin in blocking establishment of 360 colonization has previously been documented in a mouse model of carriage following systemic 361 administration of high levels of purified type-specific antibody, and in experimental human 362 pneumococcal carriage following immunization with pneumococcal conjugate vaccine (56, 61) . 363
In the current study involving naturally-acquired mucosal antibody, we demonstrate that sIgA-364 mucus interaction is necessary for efficient binding to hNF and subsequent removal of 365 agglutinated bacteria. There is evidence that sIgA specifically interacts with mucins via the 366 mucin-like hinge region of IgA1 and/or though the hydrophilic secretory component (62). In this 367 regard, secretory component ensures the appropriate localization of sIgA within the mucus and 368 thereby contributes to sIgA-mediated immune exclusion. This has been shown in the case of 369
Shigella flexneri infection of the murine gut mucosa using a monoclonal antibody modified to 370 resemble sIgA (58). Alternatively, larger particles generated by agglutination together with their 371 physical association with viscous mucus could be more efficiently swept away and cleared from 372 the nasal surfaces by the mechanics of normal mucociliary flow. 373
Our study demonstrates protection against S. pneumoniae by natural secretory 374 immunoglobulin. Our observations also raise the question whether PspC-secretory component 375 binding is beneficial for the bacterium or aids in mucus-mediated host defense. Secretory 376 component is present in the mucus in free form or bound to sIgA/sIgM. Spn binding of secretory 377 component attached to sIgA via PspC might limit Fab-dependent recognition that leads to 378 agglutination and clearance. 379 S. pneumoniae colonization is predominantly observed in children younger than 5 years 380 of age, in contrast to much lower carriage rates in healthy adults (9, 10). It is apparent that the 381 upper respiratory tract of adults is a less advantageous niche for Spn, perhaps due to the 382 presence of mucosal host defense molecules such as sIgA. In contrast to other 383 immunoglobulins, sIgA production starts late during childhood and reaches adult levels in saliva 384 around 7 years of age (63). The natural development of adaptive immunity against 385 immunogenic pneumococcal proteins reaches its maximum at 3 to 5 years of age, although 386 these observations are based on serum IgG levels (64). Likewise, anti-pilus antibodies are 387 commonly found in humans, and reach maximum levels around 10 to 15 years of age (31) . 388
Previous studies have tested for an association between pilus-expressing isolates and age of 389 the carriers in vaccinated populations, using either pilus specific PCR and whole-genome 390 sequencing to perform genotyping, but have found conflicting results (33, 35, 65) . Our results 391 from a large unvaccinated mother-infant cohort showed that pilus-expressing pneumococci were 392 more commonly found in colonized children (after maternally-derived immunoglobulin wanes) 393 when antigen-specific mucosal sIgA levels would be low. Indeed, the higher prevalence of 394 piliated strains in children suggests a colonization benefit conferred by pilus-1 in naive hosts 395 that is diminished later in life, presumable due to higher levels of specific mucosal sIgA. This 396 effect itself could contribute to higher carriage rates in young children. However, the lack of 397 independent association when controlling for genetic background means we cannot determine 398 whether this effect is causally driven by the pilus itself or other genetic features on the 399 background of piliated strains. Our experimental studies, however, were carried out with 400 isogenic strains that control for the effect of strain background. 401
In summary, our study suggests that augmenting mucosal immunity, particularly against 402 the pilus-1 shaft component RrgB, might accelerate the protection of children, who have the 403 highest carriage rates and burden of disease due to Spn. Additionally, we demonstrate how 404 natural-acquired antibody enhances bacteria-mucus interactions that promote mucosal defense. 405
Finally, we show how these effects of mucosal antibody may drive pathogen adaptation in the 406 natural host among different populations. 
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Bacterial cultivation 442
Spn strains used in this study are listed in Table 2 . Pneumococci were grown statically in tryptic 443 soy (TS) broth (BD) or in semisynthetic medium (C+Y, pH 6.8) at 37°C to an optical density of 444 0.6 at 620 nm (OD 620 ) for all in vitro experiments, or until an optical density of 1.0 for in vivo 445 colonization of mice. Alternatively, pneumococcal strains were cultivated on TS agar plates 446 supplemented with 100 μl of catalase (30,000 U/ml; Worthington Biomedical) and appropriate 447 antibiotics (200 μg/ml streptomycin, 250 μg/ml kanamycin, or 2 μg/ml chloramphenicol) 448 overnight at 37 °C and 5% CO 2 . 449
Recombinant Escherichia coli M15 strains were grown on LB agar plates supplemented with 450 100 μg/ml ampicillin at 30 °C or in liquid LB medium to mid-log phase (OD 600 = 0.8) at 200 rpm 451 on an environmental shaker. 452
453
Bacterial strains and mutant construction 454
The primers used for the construction of Spn mutants are summarized in Table 3 . In-frame and 455 unmarked deletion mutants of the pneumococcal serotype 4 strain,TIGR4, deficient for the 456 genes rrgA, rrgB, rrgC, rrgBC, or cbpA were obtained by generating a PCR product containing a 457 previously described insertion of the "sweet Janus" cassette (66). Deletion of rrgA and rrgB 458 were confirmed by dot blots with immunological detection using anti-RrgA and anti-RrgB sera. 459
Serotype 9 and 19F pneumococci lacking the rlrA pathogenicity island (pilus-1) were 460 constructed by transformation with genomic DNA isolated from strain P2454 (TIGR4Δpilus-1) 461 followed by selection on TS agar plates supplemented with 2 μg/ml chloramphenicol and two 462 rounds of back transformation. A pilus-insertion mutant of serotype 23F was obtained by 463 transformation of genomic DNA of strain P2535 (TIGR4ΔrrgA::Janus) followed by selection on 464 TS agar plates containing 250 μg/ml kanamycin followed by two rounds of back transformation. 465
The Janus insertion within the rrgA gene was replaced with a PCR product of the pilus-1 islet 466 with selection for streptomycin resistance and screening for acquisition of kanamycin-sensitivity. 467
The expression of the pilus-1 of the serotype 23F pneumococci was confirmed via dot blot as 468 described above. The pspA-deficient mutants were obtained by transformation of chromosomal 469 DNA from TIGR4ΔpspA (collection from Marc Lipsitch) or 23FΔpspA (67) into P2406 and 470 P2499, respectively, followed by selection on 200 μg/ml spectinomycin and streptomycin. The 471 iga-deletion mutant was generated by transformation of chromosomal DNA from a previously 472 described construct into P2499 (68). 
Human nasal secretions-binding assay 482
Adherence of different pneumococcal strains to human nasal fluid (hNF) was assessed in a 483 solid phase-binding assay as previously described (13, 69). To generate homogeneous 484 samples, hNF samples were sonicated for 1 s with an amplitude of 10. In brief, nasal mucus or 485 protease-treated mucus (10 µg/cavity) was immobilized in PBS in a 96-well flat-bottom plate 486 (Sarstedt) followed by centrifugation at 250 × g for 3 min and incubation overnight at 37°C. The 487 plates were gently washed three times with DMEM medium, and the wells were blocked with 488 0.1% BSA/DMEM for 2 h at room temperature. Spn cultures were grown to mid-log phase 489 (OD 620 = 0.6) and diluted in DMEM. After washing the plate with DMEM a bacterial suspension 490 of 2 x 10 4 bacteria in 100 µl was applied to the wells by centrifugation at 250 × g for 3 min at RT. 491
Interaction with hNF was allowed for at least 2 h and up to 5 h at 30°C and 5% CO 2 . Unbound 492 bacteria were recovered by collecting the supernatant and gently washing the wells 19 times 493 each with 100 µl DMEM. Adherent bacteria were lifted by adding 100 µl of 0.001% Triton X-494 100/PBS for 15 min at 30°C and 5% CO 2 followed by vigorous mixing. Unbound and adherent 495 pneumococci were quantified by plating in triplicate on TS agar plates supplemented with 496 appropriate antibiotics and incubated overnight at 30°C and 5% CO 2 . 497
For protein cleavage and carbohydrate oxidation immobilized human mucus was treated for 30 498 min with 50 µg/ml and 100 µg/ml of trypsin (with and without protease inhibitor), or 100 mM 499 sodium periodate (NaIO 4 ) in 50 mM sodium acetate buffer (pH 4.5), followed by blocking with 500 0.1% BSA/DMEM as described. Mild periodate concentrations (1 mM NaIO 4 ) leads to selective 501 oxidation of terminal sialic acid whereas higher concentration of NaIO 4 (up to 100 mM) oxidizes 502 vicinal hydroxyl groups of internal monosaccharides (70) (71) (72) . 503
In inhibition assays pneumococci were pre-incubated with 5 µg/ml of anti-RrgA, anti-RrgB, and 504 control serum, or increasing concentrations of sIgA (10-50 µg/ml), or serum IgA in a 2-fold molar 505 ratio (related to 50 µg/ml sIgA) for 30 min at 37°C and 5% CO 2 . 506 507
Flow cytometric analysis 508
The binding of soluble hNF, as well as purified sIgA, human serum IgA, lactoferrin, and human 509 serum IgG to viable pneumococci was analyzed by using flow cytometry. In brief, 5 x 10 6 510 bacteria were incubated with either 50 µg/ml human nasal secretions, increasing concentrations 511 of human sIgA (0 -25 µg/ml), serum IgA in a molar ratio of 1:1 and 1:2 compared to 25 µg/ml 512 sIgA, or increasing concentrations of lactoferrin (0 -1.0 µg/ml) and serum IgG (0-17.9 0 µg/ml) 513
for 30 min at 37 °C and 5% CO 2 in 96-well plates (U-bottom; Greiner Bio-One). Likewise, Spn 514 were also incubated with 12.5 µg/ml of proteolytically cleaved sIgA. After washing twice with 1% 515 BSA/PBS, binding of human proteins was detected using either FITC-labeled goat anti-human 516 IgA1 (1:250), rabbit anti-human lactoferrin IgG (1:500), or FITC-conjugated goat anti-human IgG 517
(1:250) followed by secondary APC-labeled anti-rabbit IgG (1:100). Antibody incubations 518 occurred in 0.1 % BSA/PBS for 45 min at 4°C. Finally, bacteria were washed and fixed with 2% 519 paraformaldehyde in PBS at RT for 1 h and fluorescence intensity was measured using a FACS 520 LSR II flow cytometer and FACSDiva software 8.0.1 (Becton Dickinson) for data acquisition and 521 analysis with FlowJo software 10.3. A gating region was set to exclude bacterial aggregates and 522 debris. The results of human protein binding to pneumococci are shown as the percentage of 523 labeled bacteria. 524 525
Heterologous expression and purification of recombinant RrgB protein 526
Purification of recombinant RrgB protein used in this study has previously been described (73). 527 C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME), and bred and 549 housed in a conventional animal facility as described (74). During colonization, all mice 550 appeared healthy and did not experience any weight loss in comparison to uninfected controls. 551
Spn strains were grown to an OD 620 = 1.0, washed and diluted to the desired density in PBS. A 552 mixture containing a 1:1 ratio of the TIGR4 strain and isogenic pilus-deficient mutant was pre-553 incubated with either human sIgA (final concentration 0.9 mg/ml in PSB), human serum IgA, or 554 PBS as control for 30 min at RT. Five-week old adult mice were inoculated intranasally without 555 anesthesia with 15 µl containing 1.5 -2 x 10 5 CFU of the mixed pneumococcal strains. At 4 h or 556 22 h post pneumococcal challenge, mice were euthanized using CO 2 followed by cardiac 557 puncture. For quantification of the colonization density, the trachea was cannulated and lavaged 558 with 200 µl of sterile PBS, and fluid collected from the nares. The nasal lavage samples were 559 plated in serial dilution on TS agar plates supplemented with 200 µg/ml spectinomycin. To 560 calculate the competitive index (CI) a colony immunoblot detecting the pilus-expressing strain 561 was performed. In brief, cultivated TS agar plates containing the total number of pneumococcal 562 colonies were blotted on circular nitrocellulose membranes. After drying for 15 minutes the 563 membrane was blocked with 2 % BSA/PBS for at least 3 h followed by the incubation with a 564 primary rabbit anti-RrgB antibody (1:200000 in 0.1% BSA/0.01% Tween 20/PBS) overnight at 565 4°C. The membrane was washed three times with 0.05% Tween 20/PBS and incubated with a 566 secondary alkaline phosphatase-coupled anti-rabbit IgG (1:5000 in 0.1% BSA/0.01% Tween 567 20/PBS) for 1 h at room temperature. The colorimetric visualization of the pilus-expressing 568 pneumococcal colonies occurred by use of NBT/BCIP as substrate. To determine the quantity of 569 the non-piliated colonies, number of pilus-expressing colonies were subtracted from the total 570 number of colonies. The competitive indices were calculated as the ratio of pilus-expressing 571 strain to pilus-deficient mutant output CFU/ml divided by the pilus-expressing strain to pilus-572 deficient mutant input CFU/ml. The colony immunoblots were performed at least in duplicates 573 from at least two independent colonization experiments to ensure reproducibility. 574 575
Agglutination assay and microscopic visualization 576
For agglutination, 5 x 10 4 bacteria were incubated with 10 µl of undiluted hNF or purified sIgA 577 (which contained same titer of anti-RrgB IgA) for 2 h at 37°C and 5% CO 2 . Samples were 578 placed onto glass slides and immobilized via heat fixation. To visualize mucus, samples were 579 incubated with 3% acetic acid followed by the incubation with alcian blue (in 3% acetic acid, pH 580 2.5) for 30 min. After washing in water for 10 min, slides were blocked in 10% FBS at 4°C 581 overnight. Bacteria were stained with primary rabbit anti-capsule antibody (1:200 in 0.5% 582 FBS/PBS) and secondary FITC-coupled goat anti-rabbit IgG (1:100 in 0.5% FBS/PBS). 583
Agglutination was visualized on an Axiovert 40 CFL microscope equipped with an Axiocam IC 584 digital camera (Zeiss). All image analysis was performed with ZEN 2012 software and images 585 were processed with ImageJ 1.52a for brightness and contrast. 586
587
SDS-PAGE and Western blot analysis 588
Western blots were performed to detect proteinaceous components in hNF. 1 µg of purified 589 lactoferrin, secretory IgA, or lysozyme, as well as pooled hNF were separated under denaturing 590 conditions using a 4-12 % Bolt Bis-Tris Plus gels (Thermo Fisher Scientific). Separated proteins 591
were transferred on nitrocellulose membranes via a dry blotting system (iBlot 2, Thermo Fisher 592 Scientific). Following blocking the membrane with 2% BSA/PBS for at least 3 h and washing 3 593 times with PBS, 0.05% Tween 20, proteins were detected with a polyclonal rabbit anti-human 594 lactoferrin antibody (1:10000), alkaline phosphatase-coupled goat anti-human IgA antibody 595
(1:20000), or a rabbit anti-human lysozyme antibody (1:10000) overnight at 4°C followed by the 596 incubation with an alkaline phosphatase-coupled goat anti-rabbit IgG (1:5000) for 1 h at RT. All 597 antibody incubations occurred in 0.1% BSA/0.01% Tween 20/PBS. Protein bands were 598 visualized after washing the membrane three times with 0.05% Tween 20/PBS using NBT/BCIP 599 as substrate. 600 601
Association between pilus and age in a human population 602
We used genomic data from the Maela refugee camp (75). This consists of around 600 children 603
and their mothers sampled every month from birth to two years of age, where 3000 randomly 604 selected positive swabs have associated genomic data available (53). We gave each sample a 605 binary outcome, mothers being positive and infants being negative; infants under six months of 606 age were excluded. 607
To determine pilus presence, we used a definition of the accessory genome in this population 608 and classified any sequence containing at least one of the three rrgB alleles (COGs CLS02709, 609 CLS03842 and CLS01960) as being piliated (30, 55) . To control for the same isolate being 610 observed multiple times, we assigned a unique identifier to each individual carriage episode, 611 which have been previously defined using a hidden Markov model (76). 612
We then used a generalized linear mixed model with a Bernoulli error structure and logit link 613 function to test for an association between pilus presence and age. Pilus presence was treated 614 as a fixed effect, and a random intercept for each carriage episode was included. We calculated 615 a p-value for the association by using a likelihood-ratio test between this model and a nested 616 model with the pilus term removed. 617
To calculate this association while also controlling for genetic background, we also used a linear 618 mixed model (LMM) with the genetic kinship between isolates as random effects, as in genome-619 wide association studies (77, 78) . We used the pyseer package (v1.2.0) in LMM mode, with the 620 kinship/covariance matrix calculated from a neighbor-joining tree of all genome sequences in 621 the cohort (53, 79) . 622 623
Statistical analyses 624
Statistical analysis was performed using GraphPad Prism (version 7.01, Inc., SanDiego, CA) . 6 (A, B, D) or 1-way ANOVA followed by Dunnett´s multiple comparison, n = 6 (C). Adherence of WT Spn an isogenic mutants, deficient for one or two pilus-1 components to hNF was assessed in a solid-phase assay. Each bacteria (1 x 10 4 / 100 µl DMEM) were incubated with 10 µg hNF in presence of 0.1 % BSA for 2 h at 30°C. Bound bacteria were determined by resuspending with 0.001% Triton X-100 following plating on TS agar plates supplemented with 200 µg/ml streptomycin. n = 5 to 18 (B) Flow cytometric analysis of sIgA-binding from soluble hNF by WT Spn and isogenic mutants. Bacteria (5 x 10 6 CFU/ 50 µl) were incubated with 50 µg/ml of hNF. Binding of surface associated sIgA was analyzed using a FITC-labeled goat anti-human IgA1 antibody and is shown as the percentage binding. n = 6 (A and B) Results of at least three independent experiments are illustrated as mean values ± S.D. *,p<0.05; ****,p<0.0001 vs. TIGR4 by 1-way ANOVA followed by Dunnett´s multiple comparison. (C) Inhibition adherence assay using pilus-1-specific antisera. Bacteria were pre-treated with each 5 µg/ml of rabbit control serum, anti-RrgA, or anti-RrgB antiserum before incubation with immobilized hNF for 2 h at 30°C. Detection of bound bacteria was analyzed as described in (A). n = 6. Results of three independent experiments are illustrated as mean values ± S.D. **,p<0.01; ****,p<0.0001 vs. w/o by 1-way ANOVA followed by Sidak´s multiple comparison. 
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Figure 6: Secretory IgA is necessary but not sufficient for pneumococcal adherence to human nasal fluid. (A) Adherence of Spn TIGR4 and isogenic pilus-1-deficient mutant to six hNF from individual donors was assessed in a solid-phase assay. Bacteria (1 x 10 4 /100 µl DMEM) were incubated with 10 µg immobilized hNF in presence of 0.1 % BSA for 2 h at 30°C. n = 6. (B) Anti-RrgB IgA was determined using an ELISA. Recombinant purified RrgB protein was immobilized in a microtiter plate (Immulon 2HB, Thermo Fisher), and, after blocking, incubated with 200 µg/ml hNF, or 25 µg/ml sIgA and serum IgA, respectively. Binding of RrgB-specific IgA was detected using a biotin-labeled anti-human IgA and peroxidase-coupled streptavidin. The values of control wells without hNF, or sIgA were subtracted from each measured value. Results are illustrated as mean values ± S.D. of two independent experiments. n = 4. (C) Inhibition adherence assay using purified sIgA in increasing concentrations or purified serum IgA in a 2-fold molar ratio (compared to 50 µg/ml sIgA). Bacteria were pre-treated with either sIgA or serum IgA for 30 min at 37°C before incubation with immobilized pooled hNF for 2 h at 30°C. n = 6. (D) Binding of wild type Spn to immobilized sIgA or BSA. Secretory IgA and BSA (each 10 µg) were immobilized overnight followed by blocking with 0.1 % BSA and incubation with 1 x 10 4 /100 µl bacteria for 2h at 30°C. n = 6. (A-C) Experiments were performed in duplicates and mean values of three independent experiments are shown with error bars corresponding to S.D. **,p<0.01; ****,p<0.0001 by 1-way ANOVA followed by Sidak´s multiple comparison (C). A and B) WT Spn and the pilus-1-deficient mutant were incubated with hNF (A) or purified human sIgA (B) for 2 h at 37°C and 5% CO 2. Mucus (blue) was stained with alcian blue and bacteria (green) were detected using rabbit anti-capsule antibody and secondary FITC-coupled goat anti-rabbit IgG. Agglutination was visualized by microscopy on an Axiovert 40 CFL microscope equipped with an Axiocam IC digital camera. (C) Adherence of Spn to supernatant of centrifuged hNF. Before immobilization, hNF was centrifuged for 5 min at 10000 xg. n = 4.
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Figure 8: Immune exclusion by pilus-1 specific sIgA. (A and B) Adult mice were intranasally (i.n.) infected with a suspension containing equal amounts of TIGR4 and isogenic pilus-1-deficient mutant. Before administration bacteria were either preincubated with sIgA, serum IgA (equal anti-RrgB titer compared to sIgA), cleaved sIgA, or PBS. Colonization density and competitive index (CI) was assessed 4 h (A) and 22 h (C) p.i. by culture of URT lavages followed by colony immunoblot using an anti-RrgB antibody. n = 5 to 13. (B) Before administration, sIgA was cleaved with recombinant IgA1-protease for 20h at 37°C. Cleavage was visualized on a denaturing and non-reducing SDS-PAGE and Western Blot. Solid arrow indicates uncleaved sIgA [400kDa] and dashed arrows indicate cleaved sIgA1 [200kDa and 50kDa]. (D) Adherence of Spn TIGR4 and isogenic iga-deficient mutant to hNF was analyzed in a solid-phase assay as described before. Results are shown as mean values of three independent experiments are shown with error bars corresponding to S.D. *,p<0.05 by two-tailed unpaired t-test. n = 6. (E) Adult mice were i.n. challenged with mutants lacking the IgA1-protease. CI was determined as described in (C). n = 8 to 9. (A, C, E) Experiments were repeated twice and groups represent n = 5 -13 animals with median ± interquartile range. Dotted line represents CI = 1. Group medians were compared to a CI = 1 by Wilcoxon signed rank test and resulting p-values are indicated. 
